CAR-T CD20 for Advanced Diffuse Large B Cell Lymphoma

Home / Clinical Studies / CAR-T CD20 for Advanced Diffuse Large B Cell Lymphoma

CAR-T CD20 for Advanced Diffuse Large B Cell Lymphoma

Chimeric Antigen Receptor T cell (CAR-T) therapy involves engineering cancer patients’ own immune cells to recognize and attack their tumors. TRIAL DATA Phase I Clinical Trial – VIEW PRESS HERE March 25, 2015

Name of StudyRedirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma
PhaseClinical Trial Phase I
ClinicalTrials.gov IdentifierNCT01735604 - view study online here
Study TypeInterventional
Study DesignEndpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Principal InvestigatorWei Dong Han, MD, PhD
Hospital(s)Chinese PLA General Hospital (PLAGH)